(VHT) Vanguard Health Care Shares - Ratings and Ratios
Pharmaceuticals, Biotech, Medical, Devices, Insurance
Dividends
| Dividend Yield | 1.04% |
| Yield on Cost 5y | 1.44% |
| Yield CAGR 5y | 9.28% |
| Payout Consistency | 96.0% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 14.7% |
| Value at Risk 5%th | 24.3% |
| Relative Tail Risk | 0.70% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.51 |
| Alpha | 2.58 |
| CAGR/Max DD | 0.36 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.356 |
| Beta | 0.532 |
| Beta Downside | 0.550 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.91% |
| Mean DD | 4.90% |
| Median DD | 3.67% |
Description: VHT Vanguard Health Care Shares October 30, 2025
The Vanguard Health Care Index Fund ETF (VHT) follows a pure indexing strategy that seeks to mirror the performance of its benchmark-a GICS-defined U.S. health-care index comprising large, mid-size, and small-cap stocks. The fund attempts to hold each constituent in roughly the same proportion as the index, investing essentially all of its assets in those securities.
Key metrics as of the latest filing: an expense ratio of 0.10 %, total assets of roughly $10 billion, and a 12-month trailing return of about +9 % (subject to market conditions). The health-care sector is driven by demographic aging (U.S. population 65+ projected to reach 21 % by 2030), sustained R&D spending (biotech R&D intensity averaging 12 % of revenue), and policy factors such as Medicare reimbursement rates. VHT’s top holdings typically include major players like UnitedHealth Group, Johnson & Johnson, and Pfizer, which together account for roughly 30 % of the fund’s net assets.
For a deeper, data-rich analysis of VHT’s risk-adjusted performance and sector exposure, you might explore the ValueRay platform to compare it against peer ETFs and identify any hidden valuation edges.
What is the price of VHT shares?
Over the past week, the price has changed by +0.16%, over one month by +1.05%, over three months by +12.20% and over the past year by +12.27%.
Is VHT a buy, sell or hold?
What are the forecasts/targets for the VHT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 300.7 | 5.4% |
VHT Fundamental Data Overview December 18, 2025
Beta = 0.66
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 17.43b USD (17.43b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 17.43b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 17.43b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.97% (E(17.43b)/V(17.43b) * Re(7.97%) + (debt-free company))
Discount Rate = 7.97% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for VHT ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle